OCT-3598 / Oscotec, Kanaph Therapeutics - LARVOL DELTA

Oscotec launches Korea phase 1 for resistance-targeting cancer drug, boosts R&D (Chosun Biz) - "Oscotec introduced OCT-598, a candidate anticancer drug to overcome resistance. In 2022, it brought in the technology from Kanaph Therapeutics and is conducting a phase 1a clinical trial in Korea. It is preparing a phase 1b clinical trial in Korea and the United States."

New P1 trial • Trial status • Gastric Cancer • Gastroesophageal Cancer • Head and Neck Cancer • HER2 Negative Breast Cancer • Non Small Cell Lung Cancer • Prostate Cancer

Inhibition of PGE2 signaling by an EP2/4 dual antagonist OCT-598 prevents acquisition of therapy-resistance and tumor relapse (AACR 2025) - "In vivo, OCT-598 abrogated tumor relapse after irradiation in CT26 mouse syngeneic tumor model, leading to complete remissions. Based on these observations, a clinical trial is set to be initiated to test the "anti-resistance" activity of OCT-598 as an adjuvant to the standard-of-care treatment in patients with advanced solid tumors."

Oncology • Solid Tumor

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=51 | Recruiting | Sponsor: Oscotec Inc.

New P1 trial • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

The anti-cancer resistance-overcoming drug candidate ‘OCT-598,’ jointly developed by the Korea Research Institute of Chemical Technology, Cana Therapeutics, and Oscotec, has officially entered the development track with the initiation of first patient dosing in a domestic Phase 1 clinical trial. (The Asia Business Daily) - "With the successful commencement of first patient dosing in the recent domestic Phase 1 trial, the original developers-the Korea Research Institute of Chemical Technology and Cana Therapeutics-received milestone payments."

Trial status • Oncology

Oscotec submits clinical trial application for next-generation anti-cancer drug in Korea (Chosun Biz) - "Oscotec announced on the 21st that it has submitted a clinical trial plan (IND) for its next-generation anti-cancer drug candidate 'OCT-598' to the Ministry of Food and Drug Safety to overcome cancer drug resistance. Last month, it received IND approval for phase 1 clinical trials from the U.S. Food and Drug Administration (FDA). This phase 1 trial will evaluate the safety, tolerability, and pharmacokinetic properties of OCT-598 in up to 51 patients with advanced solid tumors in the United States and Korea. OCT-598 is a dual-action anti-cancer drug that simultaneously inhibits the receptors EP2 and EP4 of prostaglandin E2 (PGE2)."

IND • New P1 trial • Solid Tumor

Oscotec, application for approval of clinical trial plan [Google translation] (HIT News) - "The company submitted a phase 1 clinical trial plan (IND) for OCT-598, a candidate substance for the treatment of advanced solid tumors, to the U.S. Food and Drug Administration (FDA)."

IND • New P1 trial • Solid Tumor

OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune responses in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies (AACR 2023) - "Furthermore, the addition of OCT-598 to the lung cancer standard-of-care regimen (anti-PD-1 plus chemotherapy) in TC-1 mouse lung adenocarcinoma model gave rise to complete tumor regression. In conclusion, dual blockade of EP2 and EP4 by OCT-598 is shown to be a compelling strategy to reinforce antitumor effects by thwarting PGE2-mediated therapy resistance and immune evasion.Findings from this study provide a rationale for clinical development of OCT-598 as a therapeutic option for human malignant cancers."

Combination therapy • Preclinical • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD1a • IL4